X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    New Delivery Path Brings To Light Efficacy of Immunotherapy

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    New Delivery Path Brings To Light Efficacy of Immunotherapy

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Europe

Philips enhances neurological diagnosis with the launch of IntelliSpace Portal 9.0

Yuvraj_pawp by Yuvraj_pawp
28th November 2016
in Europe, Facilities & Operation, News

As part of the 2016 Radiological Society of North America Annual Meeting (RSNA), Royal Philips announced the introduction of IntelliSpace Portal 9.0, the latest edition of its comprehensive, advanced visual analysis and quantification platform.              

Featuring a suite of multi-modality functions and expanded neurological tools, IntelliSpace Portal 9.0 helps radiologists detect, diagnose and follow-up on treatment of diseases, while using new machine learning capabilities to support the physician. The solution addresses radiologists’ needs for tools to better support the growing group of patients with brain injuries and neurological disorders such as dementia, strokes, amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).

In addition to enhancements in areas such as CT Brain Perfusion and MR T2 Perfusion IntelliSpace Portal 9.0 will offer Longitudinal Brain Imaging (LoBI)1, an application for neuro reading to support the evaluation of neurological disorders over time so clinicians can monitor disease progression. Another feature is the inclusion of the NeuroQuant® measurement application (CorTech Labs, Inc.) which enables clinicians to quantify brain volume loss.

“As the rates of dementia and neurodegeneration rise, neuroradiologists need advanced tools to help referring physicians treat these challenging cases,” said Professor Dr. Leo Wolansky, Acting Chief of Neuroradiology at University Hospitals Cleveland Medical Center in the United States. “IntelliSpace Portal 9.0 offers a comprehensive set of robust tools so neuroradiologists can quantify disease expediently.”

With more than 70 applications and enhancements of many of the core applications, IntelliSpace Portal 9.0 is a single platform for visual analysis and quantification that spans clinical domains within radiology, including neurology, oncology, and cardiology. The platform offers improved advanced 3D rendering and refined STL export that enable clinicians to print 3D models with high-levels of detail and resolution, to help understand the anatomy. IntelliSpace Portal 9.0 also includes enhancements to a host of core applications from MR Cardiac Analysis to CT TAVI planning, and System enhancements.

“Radiology has a unique ability to influence and improve outcomes, and intelligent tools enable us to empower radiologists with the right information,” said Yair Briman, Senior Vice President and General Manager of Healthcare IT for Philips. “With advances in machine learning, IntelliSpace Portal 9.0 will now be able to continually learn the usage patterns of users to enhance the important daily functions of a radiologist such as pre-preprocessing of images, encouraging faster and more streamlined diagnosis.”

IntelliSpace Portal 9.0 offers multimodality clinical applications that can be accessed from any point of the hospital network. The solution can also integrate with typical PACS and hospital information systems to allow for information to be shared broadly, helping drive collaboration across the network. With the enterprise scalability of IntelliSpace Portal 9.0, neurologists can access the power of advanced analysis virtually anywhere across their organization while maintaining consistent applications and user preferences. Some additional highlights of Version 9.0 of the Portal include:

MR Cardiac Enhancements – Facilitates easy visual scoring in various examination contexts. The package enables comprehensive functional volumetric analysis. Enhancements to the package include Whole Heart STL export for 3D printing, and enhanced workflow and batch tools.

CT Spectral Applications – Philips IntelliSpace Portal Spectral Diagnostic suite of clinical applications has been optimized for the viewing and analysis of spectral data sets from the IQon Spectral CT scanner. You can access the application you need when and where you need, virtually anywhere in your enterprise. The tools help you gain a comprehensive overview of each patient, quantify quickly, and diagnose with confidence.

IntelliSpace Portal 9.0 – part of Philips IntelliSpace integrated portfolio of healthcare informatics solutions – will be showcased at booth #6735 at the RSNA Annual Meeting, taking place Nov. 27 – Dec. 2, in Chicago, Ill. Follow @PhilipsLiveFrom or visit www.philips.com/rsna for more information on Philips’ presence at #RSNA16 and live updates from the event.

1 Pending 510(k), not available for sale in the United States.

Previous Post

The European Commission Grants VAL001 Orphan Drug Designation for the Treatment of Diffuse Large B-cell Lymphoma

Next Post

Omnicell to Acquire Leading Pharmacy Provider Ateb Inc

Related Posts

Drug Development

New Delivery Path Brings To Light Efficacy of Immunotherapy

1st April 2023
Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

£277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Next Post

Omnicell to Acquire Leading Pharmacy Provider Ateb Inc

Latest News

Drug Development

New Delivery Path Brings To Light Efficacy of Immunotherapy

1st April 2023
Cathay Cargo signs global airline partnership with Tower Cold Chain
Packaging & Logistic

Cathay Cargo signs global airline partnership with Tower Cold Chain

31st March 2023
Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

£277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In